Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531. Explore more details here.
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: WVE), whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
Wave Life Sciences’ WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on WVE stock, giving a Buy rating yesterday. Andrew Fein has given his
Wave Life Sciences gains on data for Duchenne therapy
Wave Life Sciences (WVE) stock rises on positive interim data from a Phase 2 trial for for WVE-N531, a therapy for Duchenne muscular dystrophy (DMD). Read more here.
Wave Life Sciences soars on positive DMD trial results
Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Wave Life Sciences Shares Climb Premarket on Duchenne Study Data
Shares of Wave Life Sciences rose more than 10% in premarket trading Tuesday after the clinical-stage biotechnology company reported positive interim data from a mid-stage study of its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy.
Buy Rating on Wave Life Sciences: Undervalued DMD Program and Promising Data Offer Investment Upside
Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and keeping the price target
Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...
Zacks.com on MSN1d
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage ...
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...
pharmaphorum1d
Surfing on new Duchenne data, Wave charges $175m offering
Shares in Wave rose 53% after the trial data was announced, taking its market cap above the $1 billion threshold. The company ...
Business Insider2d
Wave Life Sciences Reports Positive Data From Phase 2 FORWARD-53 Study Of WVE-N531 In DMD
(RTTNews) - Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company, Tuesday announced positive interim data from the Phase 2 FORWARD-53 study evaluating WVE-N531 in boys with Duchenne ...
BioWorld3d
Wave Life soars on WVE-N531 phase II Duchenne data
Interim phase II data of Wave Life Sciences Ltd.’s oligonucleotide, WVE-N531, revealed “impressive” dystrophin expression, ...
Yahoo Finance1d
Wave’s stock swells as it eyes approval following Phase II DMD victory
Patients in the Phase II FORWARD-53 trial (NCT04906460) benefitted from substantial dystrophin expression and the WVE-N531, ...